checkAd

     145  0 Kommentare uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease - Seite 3

    uniQure Contacts:

    FOR INVESTORS:    FOR MEDIA:
         
    Maria E. Cantor
    Direct: 339-970-7536
    m.cantor@uniQure.com     		Chiara Russo
    Direct: 617-306-9137
    c.russo@uniQure.com
    		 Tom Malone
    Direct: 339-970-7558
    t.malone@uniQure.com

    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease - Seite 3 LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient …